&nbsp;Protective effect of scutellarin on myocardial cells treated with high glucose

Wei,Xiaojuan; Li,Zhigang; Li,Shude; Yang,Jun; Fan,Biao; He,Shuiwang; Li,Siman

doi:10.3892/br.2025.2021

Protective effect of scutellarin on myocardial cells treated with high glucose

Authors:
- Xiaojuan Wei
- Zhigang Li
- Shude Li
- Jun Yang
- Biao Fan
- Shuiwang He
- Siman Li
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, School of Basic Medicine, Kunming Medical University, Kunming, Yunnan 650500, P.R. China, Department of Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China, Laboratory of Cell and Molecular Biology, Basic Medicine Experimental Teaching Center, Faculty of Basic Medical Sciences, Kunming Medical University, Kunming, Yunnan 650500, P.R. China, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan 650201, P.R. China
Published online on: June 19, 2025 https://doi.org/10.3892/br.2025.2021
Article Number: 143
Copyright: © Wei et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Diabetic cardiomyopathy (DCM) is an important cause of death in patients with diabetes. DCM can be simulated by cardiomyocyte injury induced by high glucose (HG) in vitro. Scutellarin (Scu) is a flavonoid extracted from Erigeron breviscapus. The H9c2 cell line was used as an in vitro model in the present study to investigate the mechanism by which Scu reduces HG‑induced cardiomyocyte injury. Moreover, the present study aimed to provide scientific evidence on the mechanism by which Scu prevents DCM. The following groups were used: Control, model, Scu (50/100/200/400 µM) and curcumin. Following H9c2 cell adherence, the control and model groups were treated with normal medium; the Scu group cells were treated with different concentrations of Scu, whereas the curcumin group cells were treated with 4 µM curcumin for 4 h. Subsequently, the normal group was cultured in normal medium, and the other groups were treated with medium containing 100 mM HG for 48 h. The results indicated that Scu improved the morphology of H9c2 cells treated by HG, enhanced cell proliferative activity, reduced the production of reactive oxygen species and the induction of apoptosis. Moreover, Scu promoted the expression of Bcl‑2 and inhibited the expression levels of caspase‑3, cleaved caspase‑3, caspase‑9, cleaved caspase‑9, caspase‑12, Bax, NADPH oxidase (Nox)2 and Nox4. The findings indicated that Scu could inhibit oxidative stress and reduce the induction of apoptosis in cardiomyocytes, thereby alleviating HG‑induced myocardial injury.

View Figures

View References

1	Riehle C and Bauersachs J: Of mice and men: Models and mechanisms of diabetic cardiomyopathy. Basic Res Cardiol. 114(2)2019.PubMed/NCBI View Article : Google Scholar
2	Lorenzo-Almorós A, Tuñón J, Orejas M, Cortés M, Egido J and Lorenzo Ó: Diagnostic approaches for diabetic cardiomyopathy. Cardiovasc Diabetol. 16(28)2017.PubMed/NCBI View Article : Google Scholar
3	Unger RH and Orci L: Diseases of liporegulation: New perspective on obesity and related disorders. FASEB J. 15:312–321. 2001.PubMed/NCBI View Article : Google Scholar
4	Wu Y, Reece EA, Zhong J, Dong D, Shen WB, Harman CR and Yang P: Type 2 diabetes mellitus induces congenital heart defects in murine embryos by increasing oxidative stress, endoplasmic reticulum stress, and apoptosis. Am J Obstet Gynecol. 215:366.e1–366.e10. 2016.PubMed/NCBI View Article : Google Scholar
5	Cong XQ, Piao MH, Li Y, Xie L and Liu Y: Bis(maltolato)oxovanadium(IV) (BMOV) attenuates apoptosis in high glucose-treated cardiac cells and diabetic rat hearts by regulating the unfolded protein responses (UPRs). Biol Trace Elem Res. 173:390–398. 2016.PubMed/NCBI View Article : Google Scholar
6	Xue Y, Su J, Jiang F, Wu C, Shen X and Tao L: Preparation and pharmaceutical properties of breviscapine sustained-release microspheres. Chin J Exp Trad Med Formulae. 23:7–12. 2017.(In Chinese).
7	Zhang J, Xiao F and Yang X: Biological characteristics and medicinal efficacy of Erigeron breviscapus. Lishizhen Med Mater Med Res. 2925–2926. 2007.(In Chinese).
8	Gao C, Zhou Y, Jiang Z, Zhao Y, Zhang D, Cong X, Cao R, Li H and Tian W: Cytotoxic and chemosensitization effects of scutellarin from traditional Chinese herb Scutellaria altissima L. in human prostate cancer cells. Oncol Rep. 38:1491–1499. 2017.PubMed/NCBI View Article : Google Scholar
9	Hou L, Chen L and Fang L: Scutellarin inhibits proliferation, invasion, and tumorigenicity in human breast cancer cells by regulating HIPPO-YAP signaling pathway. Med Sci Monit. 23:5130–5138. 2017.PubMed/NCBI View Article : Google Scholar
10	Zhu PT, Mao M, Liu ZG, Tao L and Yan BC: Scutellarin suppresses human colorectal cancer metastasis and angiogenesis by targeting ephrinb2. Am J Transl Res. 9:5094–5104. 2017.PubMed/NCBI
11	Li H, Fan H, Wang Z, Zheng J and Cao W: Potentiation of scutellarin on human tongue carcinoma xenograft by low-intensity ultrasound. PLoS One. 8(e59473)2013.PubMed/NCBI View Article : Google Scholar
12	Long L, Li Y, Yu S, Li X, Hu Y, Long T, Wang L, Li W, Ye X, Ke Z and Xiao H: Scutellarin prevents angiogenesis in diabetic retinopathy by downregulating VEGF/ERK/FAK/Src pathway signaling. J Diabetes Res. 2019(4875421)2019.PubMed/NCBI View Article : Google Scholar
13	Wang Y, Fan X, Fan B, Jiang K, Zhang H, Kang F, Su H, Gu D, Li S and Lin S: Scutellarin reduce the homocysteine level and alleviate liver injury in type 2 diabetes model. Front Pharmacol. 11(538407)2020.PubMed/NCBI View Article : Google Scholar
14	Liu Q, Li X, Ouyang X and Chen D: Dual effect of glucuronidation of a pyrogallol-type phytophenol antioxidant: A comparison between scutellarein and scutellarin. Molecules. 23(3225)2018.PubMed/NCBI View Article : Google Scholar
15	Bae YS, Oh H, Rhee SG and Yoo YD: Regulation of reactive oxygen species generation in cell signaling. Mol Cells. 32:491–509. 2011.PubMed/NCBI View Article : Google Scholar
16	Geiszt M, Kopp JB, Várnai P and Leto TL: Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA. 7:8010–8014. 2000.PubMed/NCBI View Article : Google Scholar
17	Huo Y, Mijiti A, Cai R, Gao Z, Aini M, Mijiti A, Wang Z and Qie R: Scutellarin alleviates type 2 diabetes (HFD/low dose STZ)-induced cardiac injury through modulation of oxidative stress, inflammation, apoptosis and fibrosis in mice. Hum Exp Toxicol. 40 (Suppl 12):S460–S474. 2021.PubMed/NCBI View Article : Google Scholar
18	Xu L, Chen R, Zhang X, Zhu Y, Ma X, Sun G and Sun X: Scutellarin protects against diabetic cardiomyopathy via inhibiting oxidative stress and inflammatory response in mice. Ann Palliat Med. 10:2481–2493. 2021.PubMed/NCBI View Article : Google Scholar
19	Sun S, Yang S, Dai M, Jia X, Wang Q, Zhang Z and Mao Y: The effect of astragalus polysaccharides on attenuation of diabetic cardiomyopathy through inhibiting the extrinsic and intrinsic apoptotic pathways in high glucose -stimulated H9C2 cells. BMC Complement Altern Med. 17(310)2017.PubMed/NCBI View Article : Google Scholar
20	E L and Jiang H: Simvastatin protects high glucose-induced H9c2 cells from injury by inducing autophagy. Pharm Biol. 58:1077–1084. 2020.PubMed/NCBI View Article : Google Scholar
21	Johnson R, Dludla P, Joubert E, February F, Mazibuko S, Ghoor S, Muller C and Louw J: Aspalathin, a dihydrochalcone C-glucoside, protects H9c2 cardiomyocytes against high glucose induced shifts in substrate preference and apoptosis. Mol Nutr Food Res. 60:922–934. 2016.PubMed/NCBI View Article : Google Scholar
22	Katayama S, Shimoda K and Takenaga Y: Loss of ADAR1 in human iPS cells promotes caspase3-mediated apoptotic cell death. Genes Cells. 20:675–680. 2015.PubMed/NCBI View Article : Google Scholar
23	Joseph EK and Levine JD: Caspase signalling in neuropathic and inflammatory pain in the rat. Eur J Neurosci. 20:2896–2902. 2004.PubMed/NCBI View Article : Google Scholar
24	Johnson CR and Jarvis WD: Caspase-9 regulation: An update. Apoptosis. 9:423–427. 2004.PubMed/NCBI View Article : Google Scholar
25	Morishima N, Nakanishi K, Takenouchi H, Shibata T and Yasuhiko Y: An endoplasmic reticulum stress-specific caspase cascade in apoptosis. Cytochrome c-independent activation of caspase-9 by caspase-12. J Biol Chem. 277:34287–34294. 2002.PubMed/NCBI View Article : Google Scholar
26	Liu MQ, Chen Z and Chen LX: Endoplasmic reticulum stress: A novel mechanism and therapeutic target for cardiovascular diseases. Acta Pharmacol Sin. 37:425–443. 2016.PubMed/NCBI View Article : Google Scholar
27	Manaenko A, Sun X, Kim CH, Yan J, Ma Q and Zhang JH: PAR-1 antagonist SCH79797 ameliorates apoptosis following surgical brain injury through inhibition of ASK1-JNK in rats. Neurobiol Dis. 50:13–20. 2013.PubMed/NCBI View Article : Google Scholar
28	Finkel T and Holbrook NJ: Oxidants, oxidative stress and the biology of ageing. Nature. 408:239–247. 2000.PubMed/NCBI View Article : Google Scholar
29	Dröge W: Free radicals in the physiological control of cell function. Physiol Rev. 82:47–95. 2002.PubMed/NCBI View Article : Google Scholar
30	Sahoo S, Meijles DN and Pagano PJ: NADPH oxidases: Key modulators in aging and age-related cardiovascular diseases? Clin Sci. 130:317–335. 2016.PubMed/NCBI View Article : Google Scholar
31	Ago T, Kuroda J, Pain J, Fu C, Li H and Sadoshima J: Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res. 106:1253–1264. 2010.PubMed/NCBI View Article : Google Scholar
32	Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD and Sadoshima J: NADPH oxidase 4 (Nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci USA. 107:15565–15570. 2010.PubMed/NCBI View Article : Google Scholar
33	Wang Y, Luo X, Pan H, Huang W, Wang X, Wen H, Shen K and Jin B: Pharmacological inhibition of NADPH oxidase protects against cisplatin induced nephrotoxicity in mice by two step mechanism. Food Chem Toxicol. 83:251–260. 2015.PubMed/NCBI View Article : Google Scholar
34	Cha JJ, Min HS, Kim KT, Kim JE, Ghee JY, Kim HW, Lee JE, Han JY, Lee G, Ha HJ, et al: APX-115, a first-in-class pan-NADPH oxidase (Nox) inhibitor, protects db/db mice from renal injury. Lab Invest. 97:419–431. 2017.PubMed/NCBI View Article : Google Scholar
35	Kwon G, Uddin MJ, Lee G, Jiang S, Cho A, Lee JH, Lee SR, Bae YS, Moon SH, Lee SJ, et al: A novel pan-Nox inhibitor, APX-115, protects kidney injury in streptozotocin-induced diabetic mice: Possible role of peroxisomal and mitochondrial biogenesis. Oncotarget. 8:74217–74232. 2017.PubMed/NCBI View Article : Google Scholar
36	American Diabetes Association. 2. Classification and diagnosis of diabetes: Standards of medical care in diabetes-2021. Diabetes Care. 44 (Suppl 1):S15–S33. 2021.PubMed/NCBI View Article : Google Scholar
37	Forbes JM and Cooper ME: Mechanisms of diabetic complications. Physiol Rev. 93:137–188. 2013.PubMed/NCBI View Article : Google Scholar
38	Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW and Grishman A: New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 30:595–602. 1972.PubMed/NCBI View Article : Google Scholar
39	Brownlee M: The pathobiology of diabetic complications: A unifying mechanism. Diabetes. 54:1615–1625. 2005.PubMed/NCBI View Article : Google Scholar
40	Cai L and Kang YJ: Oxidative stress and diabetic cardiomyopathy: A brief review. Cardiovasc Toxicol. 1:181–193. 2001.PubMed/NCBI View Article : Google Scholar
41	Dandona P, Aljada A and Bandyopadhyay A: Inflammation: The link between insulin resistance, obesity and diabetes. Trends Immunol. 25:4–7. 2004.PubMed/NCBI View Article : Google Scholar
42	Travers JG, Kamal FA, Robbins J, Yutzey KE and Blaxall BC: Cardiac fibrosis: The fibroblast awakens. Circ Res. 118:1021–1040. 2016.PubMed/NCBI View Article : Google Scholar